The increasing urbanization in low- and middle-income countries (LMICs) is closely linked to the rising prevalence of noncommunicable diseases (NCDs). NCDs are responsible for approximately 35 million deaths worldwide, accounting for 60% of all global deaths, with 80% of these occurring in LMICs.1 This dual burden of rising NCDs alongside ongoing infectious disease challenges poses significant public health challenges in these regions.
Environmental health interventions have been proven to play a pivotal role in reducing the burden of infectious diseases in LMICs. By investing in environmental health initiatives, such as hygiene measures and associated behavior change programs, pharma can make a profound impact on both public health and economic development. The reduction in infectious diseases not only alleviates the suffering caused by these illnesses but also frees up valuable resources that can be redirected toward addressing NCDs. Furthermore, it empowers healthcare resources to be focused on preventative measures for NCDs, including screening, lifestyle interventions, and vaccination.
As the disease profile in LMICs transitions towards a higher prevalence of NCDs, healthcare systems are placing more importance on establishing specialized programs and services to effectively manage chronic illnesses. Pharma companies have decades of experience and have committed substantial resources to R&D for NCD treatments, primarily in high-income country (HIC) markets. Leveraging this expertise in addressing NCDs from HIC contexts can be harnessed for the broader benefit of LMICs.
Tackling Both Types of Diseases
It’s crucial to acknowledge that the relationship between infectious diseases and NCDs in LMICs is more complex than a simple shift in focus. Both types of diseases are significant contributors to overall health challenges, and a comprehensive approach to healthcare in LMICs must address both. While NCDs are on the rise in LMICs, infectious diseases continue to pose significant threats, particularly in underserved communities. Infectious diseases often disproportionately affect vulnerable populations and can lead to devastating outbreaks if not effectively managed.
The management and prevention of NCDs require a different set of healthcare services and interventions compared to infectious diseases. NCDs often involve long-term care, lifestyle modifications, and the availability of chronic disease medications, which present unique challenges for healthcare systems.
However, the point stands: investing in hygiene interventions to reduce the burden of infectious diseases can free up resources and create a foundation for stronger communities, economies, and marketplaces. This is because a reduction in infectious diseases can lead to improved public health, a more productive workforce, lower healthcare costs, and a better quality of life for individuals. Pharma companies, in collaboration with other stakeholders, can play a crucial role in hygiene interventions, which benefit both public health and economic development.
References:
